Comment: Ipilimumab in high risk stage III melanoma

Share :
Published: 10 Oct 2016
Views: 2020
Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium

Dr De Azambuja talks to ecancertv at ESMO 2016 about the finding that ipilimumab as adjuvant therapy improved overall survival in high risk stage III melanoma.

Read the news story or watch the interview or press conference video with lead author, Prof Eggermont, for more.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.